Lamivudine Therapy Exacerbates Bilirubinemia in Patients Underlying Severely Advanced Hepatitis

다국어 초록 (Multilingual Abstract)

Lamivudine belongs to the set of antiviral agents effective against hepatitis B virus infection. Given case reports on liver injuries after certain antiviral agent treatments, this study examined the effects of lamivudine on alanine aminotransferase (ALT) and total bilirubin (TB) using a medical system database. A total of 1,321 patients taking lamivudine alone or with others were evaluated using laboratory hits in an electronic medical system at Seoul National University Hospital from 2005 through 2011. The patients were grouped according to prior ALT results: G#1, ALT < 40 IU/L; G#2, 40 IU/L ≤ ALT < 120 IU/L; G#3, 120 IU/L ≤ ALT < 240 IU/L; and G#4, ALT ≥ 240 IU/L. In G#1 and G#2 patients, lamivudine or adefovir treatment decreased ALT and TB compared to prior values. In G#3 and G#4 patients with three times the upper limit of normal (ULN) ≤ ALT < 15 times the ULN, both ALT and TB were decreased after treatment with lamivudine alone, or adefovir following lamivudine therapy, indicating that lamivudine therapy ameliorated liver functions. However, in G#4 patients who experienced severely advanced hepatitis (ALT ≥ 15 times the ULN, or ≥ 600 IU/L), lamivudine augmented TBmax (6.3→13.3 mg/dL) despite a slight improvement in ALT (839→783 IU/L), indicative of exacerbation of bilirubinemia. Patients who used adefovir after lamivudine also showed a high incidence of hyperbilirubinemia when they experienced severely advanced hepatitis. Treatment with adefovir alone did not show the effect. In conclusion, lamivudine may increase the risk of hyperbilirubinemia in patients with severely advanced hepatitis, implying that caution should be exercised when using lamivudine therapy in certain patient populations.

참고문헌 (Reference)

1 Rowland, A, "Transporter-mediated uptake of UDP-glucuronic acid by human liver microsomes: assay conditions, kinetics, and inhibition" 43 : 147-153, 2015

2 Kohn, L.T, "To Err in Human: Building a Safer Health System" National Academy Press 1999

3 Cousins, D, "The work of the National Patient Safety Agency to improve medication safety" 54 : 331-333, 2004

4 Mauben, M, "The role of data mining in pharmacovigilance" 14 : 929-948, 2007

5 Zimmerman, H.J, "The Adverse Effects of Drugs and Other Chemicals on the Liver" Lippincott Williams & Wilkins 235-249, 1999

6 Barcena, R, "Study on the efficacy and safety of adefovir dipivoxil treatment in postliver transplant patients with hepatitis B virus infection and lamivudine-resistant hepatitis B virus" 37 : 3960-3962, 2005

7 Thompson, P.D, "Statinassociated myopathy" 289 : 1681-1690, 2003

8 Bonkovsky, H. L, "Severe cholestatic hepatitis caused by thiazolidinediones:risks associated with substituting rosiglitazone for troglitazone" 47 : 1632-1637, 2002

9 Li, X, "Optimized combination therapies with adefovir dipivoxil (ADV) and lamivudine, telbivudine, or entecavir may be effective for chronic hepatitis B patients with a suboptimal response to ADV monotherapy" 8 : 21062-21070, 2015

10 Tsubota, A, "Lamivudine therapy for spontaneously occurring severe acute exacerbation in chronic hepatitis B virus infection: a preliminary study" 96 : 557-562, 2001

11 Lazarous, J, "Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies" 279 : 1200-1205, 1998

12 Jha, A. K, "Identifying adverse drug events: development of a computer-based monitor and comparison with chart review and stimulated voluntary report" 5 : 305-314, 1998

13 Korenblat, K.M, "Hyperbilirubinemia in the setting of antiviral therapy" 3 : 303-310, 2005

14 Kudo, M, "Functional hepatic imaging with receptor-binding radiopharmaceutical: clinical potential as a measure of functioning hepatocyte mass" 26 : 734-741, 2014

15 Leung, N. W. Y, "Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy" 33 : 1527-1532, 2001

16 Verhaz, A, "Experience with lamivudine treatment for severe acute hepatitis B" 142 : 703-707, 2014

17 Ben-Ari, Z, "Experience with lamivudine therapy for hepatitis B virus infection before and after liver transplantation, and review of the literature" 253 : 544-552, 2003

18 Pradeep Kumar, S, "Evaluation of adefovir & lamivudine in chronic hepatitis B: correlation with HBV viral kinetic, hepatic-necro inflammation & fibrosis" 133 : 50-56, 2011

19 Liu, C, "Entecavir and lamivudine therapy for severe acute chronic hepatitis B" 5 : 545-548, 2013

20 Uglietti, A, "Emtricitabine/tenofovir in the treatment of HIV infection:current PK/PD evaluation" 8 : 1305-1314, 2013

21 Kaplowitz, N, "Drug-induced liver disorders: introduction and overview in Drug-Induced Liver Disease" Marcel Dekker Inc 150-158, 2003

22 Ah, Y. M, "Drug-induced hyperbilirubinemia and the clinical influencing factors" 40 : 511-537, 2008

23 Tisdale, J.E, "Drug-Induced Diseases. Prevention, Detection and Management" Ameritan Society of Health-System Pharmacist Press 1004-, 2005

24 Wang, G. L, "Cost-effectiveness of Lamivudine, Telbivudine, Adefovir Dipivoxil and Entecavir on decompensated hepatitis B virus-related cirrhosis" 20 : 866-872, 2016

25 Zhang, C, "Cost-effectiveness comparison of lamivudine plus adefovir combination treatment and nucleos(t)ide analog monotherapies in Chinese chronic hepatitis B patients" 10 : 897-910, 2016

26 Wan, Z, "Combining serum cystatin C with total bilirubin improves short-term mortality prediction in patients with HBV-related acute-on-chronic liver failure" 10 : e0116968-, 2015

27 Willens, H.J, "Clopidogrel-induced mixed hepatocellular and cholestatic liver injury" 7 : 317-318, 2000

28 Brickford, C.L, "Biliary sludge and hyperbilirubinemia associated with ceftriaxone in an adult:case report and review of the literature" 25 : 1389-1395, 2005

29 이영호, "BI기술을 적용한 약물부작용감시시스템 개발" 한국콘텐츠학회 9 (9): 106-114, 2009

30 Rodriguez-Monguio, R, "Assessing the economic impact of adverse drug effects" 21 : 623-650, 2003

31 Andreea, F, "Adverse drug reactions in clinical practice: a causality assessment of a case of druginduced pancreatitis" 18 : 353-358, 2009

32 Pirmohamed, M, "Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients" 329 : 15-19, 2004

33 Perrillo, R, "Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants" 32 : 129-134, 2000

34 Peters, M. G, "Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B" 126 : 91-101, 2004